Comparative assessment of the efficacy and safety of addon treatment with Sofosbuvir-Daclatasvir”, Lithium”,and Trifluoprazine” to standard of care in three groups of patients with COVID-19

Phase 3

Recruiting

• Conditions: COVID-19.; COVID-19, virus identified; U07.1

• Registration Number: IRCT20130812014333N147
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Age over 18 years
Absolute lymphocyte count <1100 / ML or SaO2 <93

Exclusion Criteria

Pregnancy or breast-feeding
The physician's decision that the trial is not in the patient's interest
Any circumstances that do not allow the treatment protocol to be followed easily
A history of known allergies to Sofosbuvir-Velp, Trifluoprazine, Lithium and Trihexyphenidyl
Drugs that their concomitant use with standard treatment or Sofosbuvir-Velpatasvir, Trifluoprazine, Lithium, and Trihexyphenidyl are contraindicated and can not be discontinued.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ot need hospitalization, feels well, and is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill but is able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Not need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.;Need hospitalization, feels ill and isn't able to perform normal activities. Timepoint: On days 3, 5 and 10 of treatment. Method of measurement: Based on clinical examination.